19666-76-3
Chemical Structure
Panaxadiol
Synonym(s): 20(R)-Panaxadiol
- CAS No.: 19666-76-3
- Formula:C30H52O3
- Molecular Weight:460.73
IUPAC Name: (3S,5R,8R,9R,10R,12R,13R,14R,17S)-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthrene-3,12-diol
InChIKey: PVLHOJXLNBFHDX-XHJPDDKBSA-N
SMILES: C[C@@]1(CC[C@@H]2O)[C@](C[C@H]3O)([H])[C@](CC[C@@]1([H])C2(C)C)(C)[C@@]4(C)[C@@]3([H])[C@]([C@](CCC5)(C)OC5(C)C)([H])CC4
Biological Activity: Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Panaxadiol | 99.89% | Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Panaxadiol (Standard) | ≥98% | Panaxadiol (Standard) is the analytical standard of Panaxadiol. This product is intended for research and analytical applications. Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wang Z, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells. Pharmacol Res. 2020;155:104727. [Content Brief]
- [2]. Myong Hak Ri, et al. Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. J Ethnopharmacol. 2021 Dec 5;281:114370. [Content Brief]
Keywords
